225 studies found for:    "Vasculitis"
Show Display Options
Rank Status Study
1 Recruiting Pediatric Vasculitis Initiative
Conditions: Wegeners Granulomatosis;   Microscopic Polyangiitis;   Churg Strauss Syndrome;   Polyarteritis Nodosa;   Takayasu Arteritis;   Primary CNS Vasculitis;   Unclassified Vasculitis
Intervention:
2 Terminated IMPROVE: Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic Vasculitis
Conditions: ANCA Associated Systemic Vasculitis Including Wegener’s;   Granulomatosis and Microscopic Polyangiitis and;   Renal Limited Vasculitis
Interventions: Drug: Cyclophosphamide;   Drug: Mycophenolate mofetil;   Drug: Azathioprine;   Drug: Prednisone (and methylprednisolone)
3 Completed Correlation of Genetic Polymorphism and Livedo Vasculitis
Conditions: Livedo Vasculitis;   Livedoid Vasculitis;   Livedoid Vasculopathy;   Genetic Pleomorphism;   Leiden Mutation
Intervention:
4 Completed Clinical Trial of Mycophenolate Versus Cyclophosphamide in ANCA Vasculitis
Condition: Vasculitis
Interventions: Drug: mycophenolate mofetil;   Drug: cyclophosphamide
5 Recruiting Prevention of Relapses in Proteinase 3 (PR3)-Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis
Condition: Vasculitis
Intervention: Drug: azathioprine
6 Completed MMF Versus CTX in the Induction Treatment of ANCA Associated Vasculitis
Conditions: Vasculitis;   Anti-Neutrophil Cytoplasmic Antibody
Intervention: Drug: mycophenolate mofetil
7 Completed Steroids and Methotrexate to Treat Systemic Vasculitis
Conditions: Inflammation;   Vasculitis;   Wegener's Granulomatosis
Intervention: Drug: prednisone and methotrexate
8 Unknown  Alemtuzumab for ANCA Associated Refractory Vasculitis
Conditions: Vasculitis;   Microscopic Polyangiitis;   Granulomatosis With Polyangiitis;   Wegener's
Intervention: Drug: Alemtuzumab
9 Completed Anti-Cytokine Therapy for Vasculitis
Conditions: Wegener's Granulomatosis;   Renal Limited Vasculitis;   Microscopic Polyangiitis
Interventions: Biological: Infliximab;   Drug: Cyclophosphamide;   Drug: Prednisolone;   Drug: Azathioprine;   Procedure: Plasma exchange;   Drug: Mycophenolate mofetil;   Drug: Methylprednisolone
10 Withdrawn Retinoids in ANCA Small Vessel Vasculitis: Silencing Autoantigens
Condition: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Interventions: Drug: Retinoic acid;   Drug: Standard of care
11 Recruiting CMV Modulation of the Immune System in ANCA-associated Vasculitis
Conditions: ANCA Associated Vasculitis;   CMV Infection
Intervention: Drug: Valaciclovir
12 Completed Pilot Study of Rituximab Therapy for Systemic Lupus Erythematosus (SLE) and Vasculitis
Conditions: Systemic Lupus Erythematosus;   ANCA Associated Vasculitis
Intervention: Drug: Rituximab
13 Completed Comparison of Treatments to Maintain Disease Remission in Patients With Wegener's Granulomatosis and Related Vasculitis Syndromes
Conditions: Vasculitis;   Wegener's Granulomatosis
Intervention: Drug: Mycophenolate Mofetil
14 Withdrawn Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab
Condition: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Interventions: Drug: Standard of care treatment;   Drug: eculizumab
15 Completed Cyclophosphamide and Prednisone Followed by Methotrexate To Treat Vasculitides
Conditions: Vasculitis;   Wegener's Granulomatosis
Intervention:
16 Completed Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years
Conditions: Vasculitis;   Wegener's Granulomatosis;   Microscopic Polyangiitis;   Churg-Strauss Syndrome;   Polyarteritis Nodosa
Interventions: Drug: prednisone, methylprednisolone,cyclophosphamides;   Drug: Cyclophosphamide, Azathioprine,prednisone,methylprednisolone;   Drug: Mycophenolate mofetil,methotrexate
17 Recruiting Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases
Conditions: Other Specified Inflammatory Disorders of Skin or Subcutaneous Tissue;   Pyoderma Gangrenosum;   Erosive Pustular Dermatosis of the Scalp;   Sweet's Syndrome;   Behcet's Disease;   Bowel-associated Dermatosis-arthritis Syndrome;   Pustular Psoriasis;   Acute Generalized Exanthematous Pustulosis;   Keratoderma Blenorrhagicum;   Sneddon-Wilkinson Disease;   IgA Pemphigus;   Amicrobial Pustulosis of the Folds;   Infantile Acropustulosis;   Transient Neonatal Pustulosis;   Neutrophilic Eccrine Hidradenitis;   Rheumatoid Neutrophilic Dermatitis;   Neutrophilic Urticaria;   Still's Disease;   Erythema Marginatum;   Unclassified Periodic Fever Syndromes / Autoinflammatory Syndromes;   Dermatitis Herpetiformis;   Linear IgA Bullous Dermatosis;   Bullous Systemic Lupus Erythematosus;   Inflammatory Epidermolysis Bullosa Aquisita;   Neutrophilic Dermatosis of the Dorsal Hands (Pustular Vasculitis);   Small Vessel Vasculitis Including Urticarial Vasculitis;   Erythema Elevatum Diutinum;   Medium Vessel Vasculitis
Intervention: Procedure: Collection of biological samples
18 Recruiting IgA-positive Versus IgA-negative Immune Complex Vasculitis
Condition: Cutaneous Vasculitis
Intervention:
19 Terminated Abatacept in ANCA Associated Vasculitis
Condition: ANCA-associated Vasculitis
Intervention: Drug: Abatacept (Orencia)
20 Not yet recruiting Endothelin Antagonism in ANCA Vasculitis
Condition: Vasculitis
Intervention: Drug: BQ123 or BQ123/788

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years